Abstract
Menopause is a natural event, which women experience around age 50. It is defined as the final menstrual period and is preceded by many years of “menopausal transition” associated with marked biological and hormonal changes. Although it is a physiological process, especially the fluctuations and final loss of estrogen activity may have a negative impact on mental well-being; lead to vasomotor symptoms, sleep disturbances, sexual problems, cognitive decline, and depressive symptoms; and may even contribute to an upsurge in the incidence of severe mental disorders, such as depressive disorders or schizophrenic psychoses. In addition to these biological changes, for women this phase of life is often burdened with numerous psychosocial stressors, role changes, losses, and the experience of aging.
This has many implications for the clinic and for research. In the clinic the specific diagnostic and therapeutic needs of women of this age group have always to be taken into account. Appropriate treatment strategies should not only include specific psychotherapeutic and psychosocial interventions but also consider estrogen replacement where indicated in addition to standard psychiatric care. The latter of course has always to be based on a thorough individual risk-benefit assessment and decided on in close cooperation with gynecologists and the well-informed woman herself.
While many studies suggest a benefit in perimenopausal depression, there still is a lack of well-designed studies on the indications and contraindications of estrogen replacement in perimenopausal women at risk for or suffering from other mental disorders. Further research is needed, especially regarding perimenopause and schizophrenic psychoses, the relative risk of hormone replacement as compared to treatment with psychoactive drugs, or the best augmentation strategies. Last but not least, we need more research on psychotherapies addressing the specific needs of women of this age group.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albert K, Pruessner J, Newhouse P (2015) Estradiol levels modulate brain activity and negative responses to psychosocial stress across the menstrual cycle. Psychoneuroendocrinol 59:14–24. https://doi.org/10.1016/j.psyneuen.2015.04.022
Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP, Expert Consensus Panel for Depression in W (2001) The expert consensus guideline series. Treatment of depression in women. Postgrad Med (Spec No):1–107
Azcoitia I, Arevalo M-A, De Nicola AF, Garcia-Segura LM (2011) Neuroprotective actions of estradiol revisited. Trends Endocrinol Metab 22(12):467–473. https://doi.org/10.1016/j.tem.2011.08.002
Balthazart J, Ball GF (2006) Is brain estradiol a hormone or a neurotransmitter? Trends Neurosci 29(5):241–249. https://doi.org/10.1016/j.tins.2006.03.004
Barth C, Villringer A, Sacher J (2015) Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci 9:37. https://doi.org/10.3389/fnins.2015.00037
Bellot E, Rouse N, Hunter MS (2018) Reclaim the menopause: a pilot study of an evidence-based menopause course for symptom management and resilience building. Post Reprod Health. 2053369117752087. https://doi.org/10.1177/2053369117752087
Belz M, Riecher-Rössler A (2017) Geschlechtsspezifische Aspekte. In: Herpertz S, Caspar F, Lieb K (eds) Psychotherapie. Funktions- und störungsorientiertes Vorgehen. Elsevier GmbH/Urban & Fischer Verlag, München, pp 553–565
Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, Faubion S, Montori VM, Abu Dabrh AM, Zuniga Hernandez JA, Prokop LJ, Murad MH (2015) Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab 100(11):4021–4028. https://doi.org/10.1210/jc.2015-2238
Bergemann N, Abu-Tair F, Strowitzki T (2007) Estrogen in the treatment of late-onset schizophrenia. J Clin Psychopharmacol 27(6):718–720. https://doi.org/10.1097/JCP.0b013e31815a6af9
Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW (2008) Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 11(2):108–123. https://doi.org/10.1080/13697130801983921
Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR (2000) Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157(6):924–930. https://doi.org/10.1176/appi.ajp.157.6.924
Boss L, Kang DH, Marcus M, Bergstrom N (2014) Endogenous sex hormones and cognitive function in older adults: a systematic review. West J Nurs Res 36(3):388–426. https://doi.org/10.1177/0193945913500566
Boyd A, Van de Velde S, Vilagut G, de Graaf R, O’Neill S, Florescu S, Alonso J, Kovess-Masfety V (2015) Gender differences in mental disorders and suicidality in Europe: results from a large cross-sectional population-based study. J Affect Disord 173:245–254. https://doi.org/10.1016/j.jad.2014.11.002
Bromberger JT, Schott LL, Kravitz HM, Sowers M, Avis NE, Gold EB, Randolph JF Jr, Matthews KA (2010) Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Arch Gen Psychiatry 67(6):598–607. https://doi.org/10.1001/archgenpsychiatry.2010.55
Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA (2011) Major depression during and after the menopausal transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med 41(9):1879–1888. https://doi.org/10.1017/S003329171100016X
Brzezinski A, Brzezinski-Sinai NA, Seeman MV (2017) Treating schizophrenia during menopause. Menopause 24(5):582–588. https://doi.org/10.1097/gme.0000000000000772
Cintron D, Lipford M, Larrea-Mantilla L, Spencer-Bonilla G, Lloyd R, Gionfriddo MR, Gunjal S, Farrell AM, Miller VM, Murad MH (2017) Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine 55(3):702–711. https://doi.org/10.1007/s12020-016-1072-9
Cobin RH, Goodman NF, American Association of Clinical Endocrinologists and American College of Endocrinology (2017) American Association of Clinical Endocrinologists and American College of endocrinology: position statement on Menopause-2017 update. Endocr Pract 23(7):869–880. https://doi.org/10.4158/EP171828.PS
Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL (2003) Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 160(8):1519–1522. https://doi.org/10.1176/appi.ajp.160.8.1519
Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL (2006) Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 63(4):385–390. https://doi.org/10.1001/archpsyc.63.4.385
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385(9980): 1835–1842. https://doi.org/10.1016/S0140-6736(14)61687-1
Comhaire FH, Depypere HT (2015) Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part II. Climacteric 18(3):364–371. https://doi.org/10.3109/13697137.2014.985646
de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M (2013) Global consensus statement on menopausal hormone therapy. Maturitas 74(4):391–392. https://doi.org/10.1016/j.maturitas.2013.02.001
Dennerstein L, Guthrie JR, Clark M, Lehert P, Henderson VW (2004) A population-based study of depressed mood in middle-aged, Australian-born women. Menopause 11(5):563–568
Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, Whiteford HA (2013) The epidemiological modelling of major depressive disorder: application for the global burden of disease study 2010. PLoS One 8(7):e69637. https://doi.org/10.1371/journal.pone.0069637
Fink G, Sumner BE, Rosie R, Grace O, Quinn JP (1996) Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16(3):325–344
Fischer B, Gleason C, Asthana S (2014) Effects of hormone therapy on cognition and mood. Fertil Steril 101(4):898–904. https://doi.org/10.1016/j.fertnstert.2014.02.025
Freeman EW (2010) Associations of depression with the transition to menopause. Menopause 17(4):823–827. https://doi.org/10.1097/gme.0b013e3181db9f8b
Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L (2004) Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 61(1):62–70. https://doi.org/10.1001/archpsyc.61.1.62
Freeman EW, Sammel MD, Lin H, Nelson DB (2006) Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 63(4):375–382. https://doi.org/10.1001/archpsyc.63.4.375
Garcia-Moreno C, Riecher-Rössler A (eds) (2013) Violence against women and mental health. Key Issues in Mental Health, vol 178. Karger, Basel
Gillies GE, McArthur S (2010) Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev 62(2):155–198. https://doi.org/10.1124/pr.109.002071
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S (2015) Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS–cognitive and affective study. PLoS Med 12(6):e1001833. https://doi.org/10.1371/journal.pmed.1001833
Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B (2015) A role for estrogen in schizophrenia: clinical and preclinical findings. Int J Endocrinol 2015:615356. https://doi.org/10.1155/2015/615356
Goldstein JM, Jerram M, Abbs B, Whitfield-Gabrieli S, Makris N (2010) Sex differences in stress response circuitry activation dependent on female hormonal cycle. J Neurosci 30(2):431–438. https://doi.org/10.1523/jneurosci.3021-09.2010
Gonzalez-Rodriguez A, Seeman MV (2018) Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opin Pharmacother 1–13. https://doi.org/10.1080/14656566.2018.1465563
Good KP, Kopala LC, Martzke JS, Fluker M, Seeman MV, Parish B, Shapiro H, Whitehorne L (1999) Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr Res 12(3):131
Gordon JL, Girdler SS (2014) Hormone replacement therapy in the treatment of perimenopausal depression. Curr Psychiatry Rep 16(12):517. https://doi.org/10.1007/s11920-014-0517-1
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS (2018) Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiat 75(2):149–157. https://doi.org/10.1001/jamapsychiatry.2017.3998
Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F (2014) The women’s Health Initiative trial and related studies: 10 years later: a clinician’s view. J Steroid Biochem Mol Biol 142:4–11. https://doi.org/10.1016/j.jsbmb.2013.10.009
Haack S, Seeringer A, Thurmann PA, Becker T, Kirchheiner J (2009) Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 10(9):1511–1526. https://doi.org/10.2217/pgs.09.102
Häfner H, Behrens S, De Vry J, Gattaz WF (1991a) Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci 241(1):65–68
Häfner H, Riecher-Rössler A, Fätkenheuer B, Hambrecht M, Löffler W, An der Heiden W (1991b) Sex differences in schizophrenia. Psychiatr Fennica 22:123–156
Häfner H, Riecher A, Maurer K, Fatkenheuer B, Löffler W, an der Heiden W, Munk-Jorgensen P, Stromgren E (1991c) [Sex differences in schizophrenic diseases] ([Sex differences in schizophrenic diseases]). Fortschr Neurol Psychiatr 59(9):343–360
Hardy R, Kuh D (2002) Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med 55(11):1975–1988
Harlow BL, Wise LA, Otto MW, Soares CN, Cohen LS (2003) Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard study of moods and cycles. Arch Gen Psychiatry 60(1):29–36
Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA (2002) Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the heart and estrogen/progestin replacement study (HERS) trial. JAMA 287(5): 591–597. joc10108 [pii]
Hoga L, Rodolpho J, Goncalves B, Quirino B (2015) Women’s experience of menopause: a systematic review of qualitative evidence. JBI Database System Rev Implement Rep 13(8): 250–337. https://doi.org/10.11124/jbisrir-2015-1948
Jacobi F, Hofler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Hapke U, Maske U, Seiffert I, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen HU (2015) Twelve-months prevalence of mental disorders in the German health interview and examination survey for adults – mental health module (DEGS1-MH): a methodological addendum and correction. Int J Methods Psychiatr Res 24(4):305–313. https://doi.org/10.1002/mpr.1479
Joffe H, Soares CN, Cohen LS (2003) Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin North Am 26(3):563–580
Karsidag C, Karsidag A, Buyukbayrak E, Kars B, Pirimoglu M, Unal O, Turan C (2012) Comparison of effects of two different hormone therapies on mood and symptomatic postmenopausal women. Arch Neuropsychiatry 49:39–43. https://doi.org/10.4274/npa.y6107
Kornstein SG, Young EA, Harvey AT, Wisniewski SR, Barkin JL, Thase ME, Trivedi MH, Nierenberg AA, Rush AJ (2010) The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause 17(4):828–839. https://doi.org/10.1097/gme.0b013e3181d770a8
Kornstein SG, Toups M, Rush AJ, Wisniewski SR, Thase ME, Luther J, Warden D, Fava M, Trivedi MH (2013) Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the sequenced treatment alternatives to relieve depression (STAR∗D) study. J Womens Health (Larchmt) 22(2):121–131. https://doi.org/10.1089/jwh.2012.3479
Kuehner C (2003) Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr Scand 108(3):163–174
Kuehner C (2017) Why is depression more common among women than among men? Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(16)30263-2
L’Hermite M (2013) HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric 16(Suppl 1):44–53. https://doi.org/10.3109/13697137.2013.808563
Landry M, Levesque D, Di Paolo T (2002) Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76(4):214–222. 65951
Li Y, Yu Q, Ma L, Sun Z, Yang X (2008) Prevalence of depression and anxiety symptoms and their influence factors during menopausal transition and postmenopause in Beijing city. Maturitas 61(3):238–242. https://doi.org/10.1016/j.maturitas.2008.09.002
Lindamer LA, Lohr JB, Harris MJ, Jeste DV (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33(2):221–228
Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49(1):47–51. S0006-3223(00)00995-1 [pii]
Lindamer LA, Buse DC, Auslander L, Unutzer J, Bartels SJ, Jeste DV (2003) A comparison of gynecological variables and service use among older women with and without schizophrenia. Psychiatr Serv 54(6):902–904
Lumsden MA (2016) The NICE guideline – menopause: diagnosis and management. Climacteric 19(5):426–429. https://doi.org/10.1080/13697137.2016.1222483
Maki PM, Dumas J (2009) Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med 27(3):250–259. https://doi.org/10.1055/s-0029-1216278
Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, van Os J (2005) Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res 73(2–3):351–355. https://doi.org/10.1016/j.schres.2004.07.016
Markham JA (2012) Sex steroids and schizophrenia. Rev Endocr Metab Disord 13(3):187–207. https://doi.org/10.1007/s11154-011-9184-2
McCarrey AC, Resnick SM (2015) Postmenopausal hormone therapy and cognition. Horm Behav 74:167–172. https://doi.org/10.1016/j.yhbeh.2015.04.018
McCarthy MM (2008) Estradiol and the developing brain. Physiol Rev 88(1):91–124. https://doi.org/10.1152/physrev.00010.2007
McEwen BS, Milner TA (2017) Understanding the broad influence of sex hormones and sex differences in the brain. J Neurosci Res 95(1–2):24–39. https://doi.org/10.1002/jnr.23809
Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T (2018) Symptoms of menopause – global prevalence, physiology and implications. Nat Rev Endocrinol. https://doi.org/10.1038/nrendo.2017.180
Morgan ML, Cook IA, Rapkin AJ, Leuchter AF (2005) Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 66(6):774–780
Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M (2004) Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 55(4):406–412. https://doi.org/10.1016/j.biopsych.2003.08.011
NICE guideline – Menopause: diagnosis and management (2015) National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/NG23
Nolen-Hoeksema S (2012) Emotion regulation and psychopathology: the role of gender. Annu Rev Clin Psychol 8:161–187. https://doi.org/10.1146/annurev-clinpsy-032511-143109
Onalan G, Onalan R, Selam B, Akar M, Gunenc Z, Topcuoglu A (2005) Mood scores in relation to hormone replacement therapies during menopause: a prospective randomized trial. Tohoku J Exp Med 207(3):223–231
Peng W, Adams J, Sibbritt DW, Frawley JE (2014) Critical review of complementary and alternative medicine use in menopause: focus on prevalence, motivation, decision-making, and communication. Menopause 21(5):536–548. https://doi.org/10.1097/GME.0b013e3182a46a3e
Pompili A, Arnone B, Gasbarri A (2012a) Estrogens and memory in physiological and neuropathological conditions. Psychoneuroendocrinology 37(9):1379–1396. https://doi.org/10.1016/j.psyneuen.2012.01.007
Pompili A, Arnone B, Gasbarri A (2012b) Estrogens and memory in physiological and neuropathological conditions. Psychoneuroendocrinol 37(9):1379–1396. https://doi.org/10.1016/j.psyneuen.2012.01.007
Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, Rapkin AJ (2002) Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 63(Suppl 7):45–48
Riecher-Rössler A (2002) Oestrogen effects in schizophrenia and their potential therapeutic implications – review. Arch Womens Ment Health 5(3):111–118. https://doi.org/10.1007/s00737-002-0003-3
Riecher-Rössler A (2003) Oestrogens and schizophrenia. Curr Opin Psychiatry 16:187–192
Riecher-Rössler A (2005) Estrogens and schizophrenia. In: Bergemann N, Riecher-Rössler A (eds) Estrogen effects in psychiatric disorders. Springer, Wien, pp 31–52
Riecher-Rössler A (2009) Psychotic disorders and menopause: the untold story. In: Soares C, Warren M (eds) The menopausal transition – interface between gynecology and psychiatry. Key Issues in Mental Health, vol 175. Karger, Basel, pp 115–126
Riecher-Rössler A (2016) Weibliche Rollen und psychische Gesundheit. In: Wimmer-Puchinger B, Gutiérrez-Lobos K, Riecher-Rössler A (eds) Irrsinnig weiblich – Psychische Krisen im Frauenleben. Hilfestellung für die Praxis. Springer, Berlin, pp 19–34
Riecher-Rössler A (2017) Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 4(1):63–72. https://doi.org/10.1016/S2215-0366(16)30379-0
Riecher-Rössler A, de Geyter C (2007) The forthcoming role of treatment with oestrogens in mental health. Swiss Med Wkly 137(41–42):565–572. smw-11925 [pii]; 2007/41/smw-11925
Riecher-Rössler A, Häfner H (1993) Schizophrenia and oestrogens – is there an association? Eur Arch Psychiatry Clin Neurosci 242(6):323–328
Riecher-Rössler A, Kulkarni J (2011) Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci 8:155–171. https://doi.org/10.1007/7854_2010_100
Riecher-Rössler A, Löffler W, Munk-Jorgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247(4):195–208
Riecher-Rössler A, Häfner H, Dütsch-Strobel A, Stumbaum M (1998) Gonadal function and its influence on psychopathology. Arch Womens Ment Health 1:15–26
Riecher-Rössler A, Schmid C, Bleuer S, Birkhäuser M (2009) Hyperprolaktinämie unter Antipsychotika: Pathophysiologische Grundlagen, klinische Bedeutung und praktisches Vorgehen. Gynäkologische Endokrinologie 7:171–182. https://doi.org/10.1007/s10304-009-0316-7
Roberts H, Hickey M (2016) Managing the menopause: an update. Maturitas 86:53–58. https://doi.org/10.1016/j.maturitas.2016.01.007
Rössler W, Ajdacic-Gross V, Riecher-Rössler A, Angst J, Hengartner MP (2016) Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study. World Psychiatry 15(2):146–154. https://doi.org/10.1002/wps.20319
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465–1477. https://doi.org/10.1001/jama.297.13.1465
Rozenberg S, Vandromme J, Antoine C (2013) Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol 9(4):216–227. https://doi.org/10.1038/nrendo.2013.17
Rubinow DR, Johnson SL, Schmidt PJ, Girdler S, Gaynes B (2015) Efficacy of estradiol in perimenopausal depression: so much promise and so few answers. Depress Anxiety 32(8): 539–549. https://doi.org/10.1002/da.22391
Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, MJ E, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH (2010) Postmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metabol 95(7_supplement_1):s1–s66. https://doi.org/10.1210/jc.2009-2509
Santoro N, Epperson CN, Mathews SB (2015) Menopausal symptoms and their management. Endocrinol Metab Clin N Am 44(3):497–515. https://doi.org/10.1016/j.ecl.2015.05.001
Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C (2005) Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 30(4):309–315. https://doi.org/10.1016/j.psyneuen.2004.08.007
Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR (2000) Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 183(2):414–420. https://doi.org/10.1067/mob.2000.106004
Schoenaker DAJM, Jackson CA, Rowlands JV, Mishra GD (2014) Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int J Epidemiol 43(5):1542–1562. https://doi.org/10.1093/ije/dyu094
Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, Karam EG, Kovess-Masfety V, Levinson D, Medina Mora ME, Ono Y, Ormel J, Pennell BE, Posada-Villa J, Sampson NA, Williams D, Kessler RC (2009) Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 66(7):785–795. https://doi.org/10.1001/archgenpsychiatry.2009.36
Seeman MV (2012) Treating schizophrenia at the time of menopause. Maturitas 72(2):117–120. https://doi.org/10.1016/j.maturitas.2012.03.008
Seeman MV (2013) Women and schizophrenia: new findings. Neuropsychiatry (London) 3(4): 423–431. https://doi.org/10.2217/NPY.13.55
Seeman MV, Fitzgerald P (2000) Women and schizophrenia: clinical aspects. In: Castle D, McGrath J, Kulkarni J (eds) Women and schizophrenia. Cambridge University Press, Cambridge, UK, pp 35–50
Sherwin BB (2005) Estrogen and memory in women: how can we reconcile the findings? Horm Behav 47(3):371–375. https://doi.org/10.1016/j.yhbeh.2004.12.002
Shimamoto A, Rappeneau V (2017) Sex-dependent mental illnesses and mitochondria. Schizophr Res. https://doi.org/10.1016/j.schres.2017.02.025
Soares CN (2014) Mood disorders in midlife women: understanding the critical window and its clinical implications. Menopause 21(2):198–206. https://doi.org/10.1097/GME.0000000000000193
Soares CN, Almeida OP, Joffe H, Cohen LS (2001) Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 58(6):529–534
Sramek JJ, Cutler NR (2011) The impact of gender on antidepressants. In: Neill JC, Kulkarni J (eds) Biological basis of sex differences in psychopharmacology. Springer, Berlin/Heidelberg, pp 231–249. https://doi.org/10.1007/7854_2010_118
Stahl SM (2001) Effects of estrogen on the central nervous system. J Clin Psychiatry 62(5):317–318
Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol 43(2):476–493. https://doi.org/10.1093/ije/dyu038
Sturdee DW, Pines A, Archer DF, Baber RJ, Barlow D, Birkhauser MH, Brincat M, Cardozo L, de Villiers TJ, Gambacciani M, Gompel AA, Henderson VW, Kluft C, Lobo RA, MacLennan AH, Marsden J, Nappi RE, Panay N, Pickar JH, Robinson D, Simon J, Sitruk-Ware RL, Stevenson JC (2011) Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 14(3):302–320. https://doi.org/10.3109/13697137.2011.570590
Taylor M (2015) Complementary and alternative approaches to menopause. Endocrinol Metab Clin N Am 44(3):619–648. https://doi.org/10.1016/j.ecl.2015.05.008
The 2017 hormone therapy position statement of The North American Menopause Society (2017) Menopause 24(7):728–753. https://doi.org/10.1097/gme.0000000000000921
Toffol E, Heikinheimo O, Partonen T (2015) Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review. Menopause 22(5):564–578. https://doi.org/10.1097/GME.0000000000000323
Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. https://doi.org/10.4088/JCP.10m06610
Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD (2007) Influence of menopause on mood: a systematic review of cohort studies. Climacteric 10(6):448–465. https://doi.org/10.1080/13697130701611267
Vivian-Taylor J, Hickey M (2014) Menopause and depression: is there a link? Maturitas 79(2): 142–146. https://doi.org/10.1016/j.maturitas.2014.05.014
Wang Q, Dong X, Wang Y, Li X (2018) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health 21(1):31–41. https://doi.org/10.1007/s00737-017-0773-2
Watson CS, Alyea RA, Cunningham KA, Jeng YJ (2010) Estrogens of multiple classes and their role in mental health disease mechanisms. Int J Women’s Health 2:153–166
Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, O’Donnell M, Galletly C, Liu D, Balzan R, Short B, Pellen D, Curtis J, Carr VJ, Kulkarni J, Schofield PR, Weickert CS (2015) Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry 20(6):685–694. https://doi.org/10.1038/mp.2015.11
Weissman MM (2000) Depression and gender: implications for primary care. J Gend Specif Med 3(7):53–57
Wharton W, Gleason CE, Miller VM, Asthana S (2013) Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res 1514:12–17. https://doi.org/10.1016/j.brainres.2013.04.011
Yazdkhasti M, Simbar M, Abdi F (2015) Empowerment and coping strategies in menopause women: a review. Iran Red Crescent Med J 17(3):e18944. https://doi.org/10.5812/ircmj.18944
Young EA, Midgley AR, Carlson NE, Brown MB (2000) Alteration in the hypothalamic-pituitary-ovarian axis in depressed women. Arch Gen Psychiatry 57(12):1157–1162
Zweifel JE, O’Brien WH (1997) A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22(3):189–212
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Riecher-Rössler, A. (2020). Menopause and Mental Health. In: Chandra, P., Herrman, H., Fisher, J., Riecher-Rössler, A. (eds) Mental Health and Illness of Women. Mental Health and Illness Worldwide. Springer, Singapore. https://doi.org/10.1007/978-981-10-2369-9_9
Download citation
DOI: https://doi.org/10.1007/978-981-10-2369-9_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2367-5
Online ISBN: 978-981-10-2369-9
eBook Packages: Behavioral Science and PsychologyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences